Moreover, clinical trials showed the efficacy of chemotherapy in reducing the frequency of CD4+CD25+FoxP3+ Tregs and their suppressive function in the circulation of patients with hepatocellular carcinoma [154] and in tumor tissues of breast cancer patients [155]. Here, FOXP3 is linked to breast carcinoma.